Lipoxin A(4) levels in asthma: relation with disease severity and aspirin sensitivity

ÇELİK G. E., Erkekol F. O., Misirligil Z., Melli M.

CLINICAL AND EXPERIMENTAL ALLERGY, cilt.37, sa.10, ss.1494-1501, 2007 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 37 Sayı: 10
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1111/j.1365-2222.2007.02806.x
  • Dergi Adı: CLINICAL AND EXPERIMENTAL ALLERGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1494-1501
  • Anahtar Kelimeler: aspirin, aspirin-exacerbated respiratory disease, asthma, 15-epi-lipoxin A(4) inflammation, lipoxin A(4), severity, PERIPHERAL-BLOOD LEUKOCYTES, NASAL POLYPS, CYSTEINYL-LEUKOTRIENES, ANTI-INFLAMMATION, PROSTAGLANDIN E-2, LIPID MEDIATORS, CYCLOOXYGENASE, EXPRESSION, TOLERANT, HYPERSENSITIVITY
  • Ankara Üniversitesi Adresli: Evet

Özet

Background Lipoxin (LX) A(4), an endogenous anti-inflammatory eicosanoid, has been found to be low in patients with severe asthma. However, few studies also suggested more diminished LX A(4) levels in aspirin-exacerbated respiratory disease (AERD) when compared with aspirin-tolerant asthma (ATA). It is, therefore, currently not clear whether the asthma severity or the presence of AERD has a primary role in the disturbed LX metabolism.